Vistagen Therapeutics提交8-K,披露fasedienol与FDA讨论后的监管进展
Vistagen Therapeutics, Inc. (0001411685) (Filer)
Vistagen Therapeutics于11月9日宣布,公司与美国FDA举行了近期的Type C会议,讨论候选药物fasedienol用于社交焦虑障碍的潜在注册路径。公司称,8-K及附件包含对FDA反馈、拟议临床与监管路径及未来试验的前瞻性陈述;FDA可能要求补充研究或资料,后续试验及审批结果仍不确定。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 9, 2026
Vistagen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-54014 | 20-5093315 | ||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
343 Allerton Ave.
South San Francisco, California 94080
(Address of principal executive offices)
(650) 577-3600
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, par value $0.001 per share | VTGN | Nasdaq Capital Market | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o
Item 8.01 Other Events
On November 9, 2026, Vistagen Therapeutics, Inc. (the “Company”) announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration (“FDA”) to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social anxiety disorder (“SAD”). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Forward-looking Statements
This Current Report on Form 8-K and Exhibit 99.1 hereto contain certain forward-looking statements within the meaning of the federal securities laws including, without limitation, statements regarding the Company’s interpretation of FDA feedback concerning future development plans for fasedienol, its proposed clinical development and regulatory pathway of fasedienol for the treatment of SAD, the design, timing and potential outcomes of future clinical trials of fasedienol, including the Company’s proposed study using the Liebowitz Social Anxiety Scale (“LSAS”) as a primary endpoint in a future Phase 3 study, the potential sufficiency of existing clinical data and the outcome of future Phase 3 studies to support a future New Drug Application, fasedienol’s potential to benefit a broad population of patients with SAD, and the Company's ability to secure sufficient financing to advance its development plans. These forward-looking statements involve known and unknown risks and uncertainties and are based on assumptions that, while considered reasonable by the Company, are inherently uncertain. Actual results may differ materially from those expressed or implied. There can be no assurance that FDA feedback will result in a successful registrational pathway, that future clinical trials will demonstrate the safety and efficacy of fasedienol for either the overall or acute treatment of SAD, that existing clinical evidence and future study outcomes will be sufficient to support regulatory approval, or that the Company will obtain the financing necessary to advance its development plans. The FDA may require additional studies or information, and there can be no guarantee that fasedienol or any other of the Company’s product candidates will receive regulatory approval or be commercially successful. These risks and other important factors are discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and other filings with the U.S. Securities and Exchange Commission (“SEC”), available at www.sec.gov. Readers should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update them except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits Index
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by Vistagen Therapeutics, Inc., dated November 9, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Vistagen Therapeutics, Inc. | ||||||||
| Date: November 9, 2026 | By: | /s/ Shawn K. Singh | ||||||
| Shawn K. Singh President and Chief Executive Officer | ||||||||
来源:SEC EDGAR · 本站存档